logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11738010 B1

PDFFull Text
Date of Patent:
Aug. 29, 2023

Filed:

Jul. 26, 2021

Oxazolidinones as taro inhibitors

Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

John P. Caldwell, Ringwood, NJ (US);

Reynalda De Jesus, East Brunswick, NJ (US);

Fa-Xiang Ding, Staten Island, NY (US);

Charles J. Gill, Beachwood, NJ (US);

Ginny Dai Ho, Murray Hill, NJ (US);

Sookhee N. Ha, Warren, NJ (US);

Sandra J. Koseoglu, Fanwood, NJ (US);

Marc A. Labroli, West Point, PA (US);

Sang Ho Lee, Berkeley Heights, NJ (US);

Christina Madsen-Duggan, Scotch Plains, NJ (US);

Mihir Mandal, Westfield, NJ (US);

Terry Roemer, Cranford, NJ (US);

Jing Su, Scotch Plains, NJ (US);

Christopher Michael Tan, Scotch Plains, NJ (US);

Zheng Tan, Westfield, NJ (US);

Haifeng Tang, Metuchen, NJ (US);

Hao Wang, Scotch Plains, NJ (US);

Christine Yang, New Brunswick, NJ (US);

Shu-Wei Yang, Edison, NJ (US);

Assignee:

MERCK SHARP & DOHME CORP., Rahway, NJ (US);

Attorney:

Meagher Emanuel Laks Goldberg & Liao, LLP

Primary Examiner:

Umamaheswari Ramachandran

Int. Cl.
CPC ...
A61K 31/4439 (2006.01); A61P 31/04 (2006.01); A61K 31/407 (2006.01); A61K 31/421 (2006.01); A61K 31/422 (2006.01); A61K 31/427 (2006.01); A61K 31/431 (2006.01); A61K 31/4375 (2006.01); A61K 31/438 (2006.01); A61K 31/4709 (2006.01); A61K 31/5377 (2006.01); A61K 31/5383 (2006.01); C07D 263/26 (2006.01); C07D 413/04 (2006.01); C07D 413/06 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01); C07D 491/048 (2006.01); C07D 495/04 (2006.01); C07D 498/04 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4439 (2013.01); A61K 31/407 (2013.01); A61K 31/421 (2013.01); A61K 31/422 (2013.01); A61K 31/427 (2013.01); A61K 31/431 (2013.01); A61K 31/438 (2013.01); A61K 31/4375 (2013.01); A61K 31/4709 (2013.01); A61K 31/5377 (2013.01); A61K 31/5383 (2013.01); A61P 31/04 (2018.01); C07D 263/26 (2013.01); C07D 413/04 (2013.01); C07D 413/06 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 491/048 (2013.01); C07D 495/04 (2013.01); C07D 498/04 (2013.01);
Abstract

Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a β-lactam antibiotic.

Find Patent Forward Citations

Loading…